#United States #San Diego #Ajinomoto Bio-Pharma #Forge Biologics #CDMO Leadership

Ajinomoto Bio-Pharma Services Wins CDMO Leadership Awards

Ajinomoto Bio-Pharma Services, well-regarded for its expertise in biopharmaceutical contract development and manufacturing, has made headlines by clinching the prestigious CDMO Leadership Awards. This year, the organization garnered accolades in the Global Biologics category, while its subsidiary, Forge Biologics, took home award recognition in Global Cell & Gene Therapy. This news was officially announced on March 20, 2025, during a ceremony celebrating excellence in the industry.

The CDMO Leadership Awards are uniquely significant as they are based on direct feedback from clients who have engaged with these companies on outsourced projects within the previous two years. Out of 210 contract manufacturers evaluated based on various performance metrics, Ajinomoto Bio-Pharma and Forge received glowing endorsements highlighting their commitment to quality and service. This year's selection process emphasized genuine experiential data, ensuring that the winning companies were indeed recognized for tangible accomplishments in their partnerships.

Yasuyuki Otake, Corporate Executive at Ajinomoto Co., expressed pride in this recognition, highlighting that it reflects the trust clients place in the company: "We are honored to be recognized as a global CDMO leader. This achievement is especially meaningful because it reflects feedback from our clients—those who trust us to help bring their transformative treatments to patients. It is particularly exciting to see Forge Biologics, the newest member of the Aji Bio-Pharma group, recognized for its leadership in cell and gene therapy as a CDMO supporting developers in advancing treatments for genetic diseases. Together with our partners, we remain dedicated to providing exceptional service for our clients and the patients they serve."

The Significance of the Awards

The awards presented by Life Science Leader and Outsourced Pharma aim to elevate standards in the contract development and manufacturing organization (CDMO) sector. They not only serve as a benchmarking tool but also recognize firms that demonstrate outstanding performance in various aspects including quality, reliability, and customer service.

Ajinomoto Bio-Pharma Services has set a high bar in the industry with its comprehensive range of offerings that cater to both small and large molecule active pharmaceutical ingredients (APIs), as well as innovative gene therapies. With facilities strategically located in Belgium, the United States, Japan, and India, the organization is well-positioned to meet diverse client needs across the globe. Their variety of innovative platforms includes Corynex® protein expression technology, oligonucleotide synthesis, and antibody-drug conjugate (ADC) services, among many others.

Continued Commitment to Quality and Service

Ajinomoto Bio-Pharma Services is incessantly striving to enhance its service quality, ensuring that it meets and exceeds client expectations. The company’s dedication to maintaining high standards is critical, particularly in the biopharmaceutical arena, where product quality and safety can significantly impact patient outcomes.

In gaining these awards, Ajinomoto Bio-Pharma and Forge Biologics not only underscore their individual competencies but also reaffirm the essence of collaboration in achieving advancements in healthcare. The endorsements from customers serve as a testament to their commitment to excellence, fostering trust between them and those who rely on their services.

As Ajinomoto Bio-Pharma Services celebrates this significant accolade, it also reaffirms its dedication to being a partner in the healthcare ecosystem, working tirelessly to aid in the development of transformative treatment solutions for various diseases.

For more information about Ajinomoto Bio-Pharma Services and their offerings, visit www.AjiBio-Pharma.com.